1. Home
  2. FENG vs CUE Comparison

FENG vs CUE Comparison

Compare FENG & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Phoenix New Media Limited

FENG

Phoenix New Media Limited

HOLD

Current Price

$1.70

Market Cap

20.8M

Sector

Industrials

ML Signal

HOLD

Logo Cue Biopharma Inc.

CUE

Cue Biopharma Inc.

HOLD

Current Price

$31.74

Market Cap

17.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FENG
CUE
Founded
1998
2014
Country
China
United States
Employees
N/A
N/A
Industry
Broadcasting
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
20.8M
17.6M
IPO Year
2011
2017

Fundamental Metrics

Financial Performance
Metric
FENG
CUE
Price
$1.70
$31.74
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$120.00
AVG Volume (30 Days)
2.8K
7.6M
Earning Date
05-12-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
61.11
EPS
N/A
N/A
Revenue
N/A
$27,466,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
195.75
52 Week Low
$1.63
$0.17
52 Week High
$3.65
$41.42

Technical Indicators

Market Signals
Indicator
FENG
CUE
Relative Strength Index (RSI) 42.98 73.24
Support Level N/A $0.40
Resistance Level $1.84 N/A
Average True Range (ATR) 0.04 5.74
MACD -0.00 2.02
Stochastic Oscillator 0.00 74.86

Price Performance

Historical Comparison
FENG
CUE

About FENG Phoenix New Media Limited

Phoenix New Media Ltd is a media company providing premium content on an integrated platform across the internet, mobile and TV channels in China. The company organizes its operations into two main segments: Net advertising services and Paid services. It provides its content and services through three channels: ifeng.com channel, video channel, and mobile channel. The company also offers a wide range of paid services including mobile value-added services, games, and content sales. It generates the majority of its revenue from Net advertising services. Geographically, it derives revenue from China.

About CUE Cue Biopharma Inc.

Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.

Share on Social Networks: